FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386419016> ?p ?o ?g. }

• W4386419016 abstract "Introduction Carbapenem-resistant Enterobacterales (CRE) and multidrug-resistant Pseudomonas aeruginosa (MDR-PA) infections are associated with a high risk of morbidity, mortality, and treatment costs. We aimed to evaluate in vitro , in vivo and clinical studies comparing the efficacy of ceftazidime-avibactam (CZA) combination regimens with CZA alone against CRE and/or MDR-PA isolates or infections. Methods We systematically reviewed the relevant literature in CINAHL/MEDLINE, Pubmed, Cochrane, Web of Science, Embase, and Scopus until December 1, 2022. Review articles, grey literature, abstracts, comments, editorials, non-peer reviewed articles, non-English articles, and in vitro synergy studies conducted on single isolates were excluded. Results 22 in vitro , 7 in vivo and 20 clinical studies were evaluated. In vitro studies showed reliable synergy between CZA and aztreonam against metallo-β-lactamase (MBL)-producing isolates. Some studies indicated good in vitro synergy between CZA and amikacin, meropenem, fosfomycin and polymyxins against CRE isolates. For MDR-PA isolates, there are comparatively fewer in vitro or in vivo studies. In observational clinical studies, mortality, clinical cure, adverse events, and development of CZA resistance after exposure were generally similar in monotherapy and combination therapy groups. However, antibiotic-related nephrotoxicity and infection relapses were higher in patients receiving CZA combination therapies. Discussion The benefit, if any, of CZA combination regimens in MDR-PA infections is elusive, as very few clinical studies have included these infections. There is no currently documented clinical benefit for the use of CZA combination regimens rather than CZA monotherapy. CZA combined with aztreonam for serious infections due to MBL producers should be evaluated by randomized controlled trials. Systematic review registration https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=278552 , CRD42021278552." @default.
• W4386419016 created "2023-09-05" @default.
• W4386419016 creator A5016590549 @default.
• W4386419016 creator A5025716337 @default.
• W4386419016 creator A5053401736 @default.
• W4386419016 creator A5058005775 @default.
• W4386419016 creator A5070202205 @default.
• W4386419016 date "2023-09-04" @default.
• W4386419016 modified "2023-10-06" @default.
• W4386419016 title "In vitro, in vivo and clinical studies comparing the efficacy of ceftazidime-avibactam monotherapy with ceftazidime-avibactam-containing combination regimens against carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa isolates or infections: a scoping review" @default.
• W4386419016 cites W1989035014 @default.
• W4386419016 cites W2060069054 @default.
• W4386419016 cites W2075287054 @default.
• W4386419016 cites W2134340025 @default.
• W4386419016 cites W2142343447 @default.
• W4386419016 cites W2155745552 @default.
• W4386419016 cites W2173640951 @default.
• W4386419016 cites W2492495737 @default.
• W4386419016 cites W2519197882 @default.
• W4386419016 cites W2557839450 @default.
• W4386419016 cites W2587434779 @default.
• W4386419016 cites W2606722213 @default.
• W4386419016 cites W2612800330 @default.
• W4386419016 cites W2618911885 @default.
• W4386419016 cites W2624551537 @default.
• W4386419016 cites W2713618701 @default.
• W4386419016 cites W2760122038 @default.
• W4386419016 cites W2766370714 @default.
• W4386419016 cites W2770745290 @default.
• W4386419016 cites W2771891407 @default.
• W4386419016 cites W2781043654 @default.
• W4386419016 cites W2789487757 @default.
• W4386419016 cites W2792380978 @default.
• W4386419016 cites W2793118730 @default.
• W4386419016 cites W2805406164 @default.
• W4386419016 cites W2807053173 @default.
• W4386419016 cites W2808163815 @default.
• W4386419016 cites W2883234304 @default.
• W4386419016 cites W2884526550 @default.
• W4386419016 cites W2886143224 @default.
• W4386419016 cites W2891378911 @default.
• W4386419016 cites W2901851195 @default.
• W4386419016 cites W2945977405 @default.
• W4386419016 cites W2946227362 @default.
• W4386419016 cites W2947057449 @default.
• W4386419016 cites W2951787891 @default.
• W4386419016 cites W2958813269 @default.
• W4386419016 cites W2966197838 @default.
• W4386419016 cites W2969547429 @default.
• W4386419016 cites W2969777541 @default.
• W4386419016 cites W2978732478 @default.
• W4386419016 cites W2990218567 @default.
• W4386419016 cites W2997008922 @default.
• W4386419016 cites W3004338125 @default.
• W4386419016 cites W3007464332 @default.
• W4386419016 cites W3022122974 @default.
• W4386419016 cites W3026777707 @default.
• W4386419016 cites W3037338473 @default.
• W4386419016 cites W3039174242 @default.
• W4386419016 cites W3045885780 @default.
• W4386419016 cites W3091054547 @default.
• W4386419016 cites W3110298378 @default.
• W4386419016 cites W3126415404 @default.
• W4386419016 cites W3129893448 @default.
• W4386419016 cites W3133086699 @default.
• W4386419016 cites W3150381630 @default.
• W4386419016 cites W3153252294 @default.
• W4386419016 cites W3176489392 @default.
• W4386419016 cites W3182835718 @default.
• W4386419016 cites W3185061976 @default.
• W4386419016 cites W3200372697 @default.
• W4386419016 cites W4200250437 @default.
• W4386419016 cites W4205774220 @default.
• W4386419016 cites W4206677002 @default.
• W4386419016 cites W4210281883 @default.
• W4386419016 cites W4210829610 @default.
• W4386419016 cites W4213042513 @default.
• W4386419016 cites W4213149563 @default.
• W4386419016 cites W4220921377 @default.
• W4386419016 cites W4224266833 @default.
• W4386419016 cites W4241884576 @default.
• W4386419016 cites W4283660278 @default.
• W4386419016 cites W4297037737 @default.
• W4386419016 cites W4304187878 @default.
• W4386419016 cites W4309244714 @default.
• W4386419016 cites W4309503005 @default.
• W4386419016 cites W4312129598 @default.
• W4386419016 cites W4319661295 @default.
• W4386419016 cites W4319869884 @default.
• W4386419016 doi "https://doi.org/10.3389/fmed.2023.1249030" @default.
• W4386419016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37727767" @default.
• W4386419016 hasPublicationYear "2023" @default.
• W4386419016 type Work @default.
• W4386419016 citedByCount "0" @default.
• W4386419016 crossrefType "journal-article" @default.
• W4386419016 hasAuthorship W4386419016A5016590549 @default.
• W4386419016 hasAuthorship W4386419016A5025716337 @default.
• W4386419016 hasAuthorship W4386419016A5053401736 @default.
• W4386419016 hasAuthorship W4386419016A5058005775 @default.
• W4386419016 hasAuthorship W4386419016A5070202205 @default.

• next